October 2010, Cambridge, UK – BioWisdom Ltd (BioWisdom), the market leader in delivering healthcare intelligence to the pharmaceutical industry, today announces a further 3 year agreement with AstraZeneca.
AstraZeneca has been a major partner in the development and exploitation of BioWisdom’s Safety Intelligence Program (SIP) since the program initiation in 2007. Since then, the Safety Intelligence Program has become a key tool for predictive toxicology at AstraZeneca, and the implementation of the Program won the BioIT Best Practices award in 2009.
The Safety Intelligence Program applies state-of-the-art technology and methodology to derive highly structured information from publicly accessible sources, which enables more effective searching, retrieval and analysis of prior knowledge in toxicology. The Program is used to support drug safety risk assessment at various stages of the drug discovery process.
BioWisdom also applies this same technology to AstraZeneca’s own internal toxicity reports, allowing AstraZeneca scientists the best views of public and proprietary safety knowledge for compounds in both the clinical and preclinical settings.
“Implementation of the Safety Intelligence Program at AstraZeneca is delivering real value in drug research and development.” said Dr David Cook, Global Safety Assessment, AstraZeneca. “Providing AstraZeneca’s scientists with desktop access to both internal and public toxicology information and knowledge is a key part of our strategies to improve the early identification and understanding of safety in our projects. Working with BioWisdom and the Safety Intelligence Program enables us to do this in a highly integrated and effective way and we look forward to continuing our strong collaboration with BioWisdom in this important area.”
“We are delighted that AstraZeneca has decided to continue their partnership with BioWisdom’s Safety Intelligence Program. We see this long term commitment as a testimony to the benefits that AstraZeneca has already experienced in working with us over the past three years in this program,” said Dr. Gordon Baxter, CEO.
Financial terms of the agreement were not disclosed.
ABOUT BIOWISDOM LTD.
BioWisdom delivers intelligence for the Healthcare Industry and helps clients to navigate the complex scientific and commercial issues involved in developing successful healthcare products. The company provides a powerful suite of software tools for the acquisition, integration, visualization and high value analysis of healthcare intelligence. The BioWisdom team combines extensive experience of the pharmaceutical and biotechnology industries with proven expertise in life science software development.
For more information, please visit: www.biowisdom.com.
ABOUT ASTRAZENECA PLC
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009.
For more information please visit: www.astrazeneca.com.
